Biofrontera AG Stock

B8FK

DE000A4BGGM7

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 09:48:16 2025-12-05 am EST			5-day change	1st Jan Change
2.690 ^EUR	0.00%		-1.82%	+25.12%

Nov. 13	Medical device maker Biofrontera Q3 revenue falls more than expected on advanced purchases in 2024	RE
Oct. 22	Biofrontera Inc. completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG.	CI

News in other languages: Biofrontera AG

Nov. 28	Biofrontera : Quartalsmitteilung zum 3. Quartal Q3/2025 (Biofrontera AG Quartalsmitteilung Q3 2025 DE)
Sep. 29	Biofrontera : Halbjahresbericht H1/2025 (Halbjahresbericht H1 2025)
May. 30	Biofrontera : Quartalsmitteilung zum 1. Quartal Q1/2025 (Quartalsmitteilung fuer das erste Quartal 2025)
May. 28	Biofrontera : Abstimmungsergebnis Übersicht 28.05.2025 (Abstimmungsergebnis UEbersicht 28.05.2025)
May. 27	NACHBÖRSE/XDAX +0,2% auf 24.286 Pkt

More news

Managers and Directors: Biofrontera AG

Manager	Title	Age	Since
María del Pilar de la Huerta Martínez DFI	Director of Finance/CFO	56	2022-09-11

Director	Title	Age	Since
Heikki Lanckriet BRD	Director/Board Member	69	2021-12-13
Helge Lubenow CHM	Chairman	57	2024-05-09
Karlheinz Schmelig BRD	Director/Board Member	-	2021-12-13

More insiders

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

Employees

Sector

Pharmaceuticals

Calendar

Jun. 02 - Q1 2026 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-03	2.690 €	+0.37%	382
25-12-03	2.680 €	0.00%	500
25-12-02	2.680 €	-1.47%	1,737
25-12-01	2.720 €	0.00%	1
25-11-28	2.720 €	-0.73%	0

End-of-day quote Xetra, December 03, 2025

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Capitalization	16.35M 19.06M 15.29M 14.28M 26.58M 1.71B 28.8M 179M 69.21M 809M 71.55M 70.02M 2.95B	P/E ratio 2023	-40.1x	P/E ratio 2024	-2.99x
Enterprise value	13.99M 16.31M 13.08M 12.22M 22.75M 1.47B 24.64M 153M 59.22M 692M 61.22M 59.92M 2.52B	EV / Sales 2023	0.73x	EV / Sales 2024	0.49x
Free-Float	70.47%	Yield 2023 *	-	Yield 2024	-

Nov. 13	Medical device maker Biofrontera Q3 revenue falls more than expected on advanced purchases in 2024	RE
Oct. 22	Biofrontera Inc. completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG.	CI
Sep. 16	Biofrontera Says Last Patient Out in Phase 3 Trial of Ameluz Photodynamic Therapy to Treat Skin Condition	MT
Jun. 29	Biofrontera Inc. signed an agreement to acquire US Assets related to Ameluz and RhodoLED of Biofrontera AG.	CI
May. 29	Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
May. 27	Biofrontera Says Co And Units Have Entered Into An Agreement With Biofrontera Inc About How To Settle Payment Obligations By Biofrontera Inc	RE
Mar. 05	Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2024	CI
Jan. 08	Biofrontera Says Last Patient Completes 1-Year Follow-Up in Skin Cancer Treatment Study; Shares Jump	MT
Nov. 30	Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
Nov. 22	Biofrontera Shares Jump After Closing Private Placement of $4.2 Million Convertible Note	MT
Nov. 21	Biofrontera AG announced that it has received $4.2 million in funding	CI
Nov. 13	Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $9M	MT
24-10-01	Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2024	CI

Nov. 28	Biofrontera : Quarterly Report 3rd Quarter Q3/2025 (Biofrontera AG Quarterly report Q3 2025 EN)	PU
Sep. 29	Biofrontera : Half-Year Financial Report H1/2025 (Half Year Financial Report H1 2025)	PU
May. 30	Biofrontera : Quarterly Report 1st Quarter Q1/2025 (Quarterly report for the first quarter of 2025)	PU
May. 27	Biofrontera : Compensation report 2024 incl. audit opinion (Verguetungsbericht 2024 EN)	PU
Apr. 30	Biofrontera : Corporate Governance Statement of Biofrontera AG pursuant to Sections 289f, 315d HGB for the financial year 2025	PU

1 week	-1.82%
Current month	-1.10%
1 month	-3.58%
3 months	+5.49%
6 months	+6.75%
Current year	+25.12%

1 week	2.65	2.77
1 month	2.58	2.86
Current year	2.1	2.96
1 year	2.08	2.96
3 years	2.08	33.6
5 years	2.08	76.34
10 years	2.08	169.47

Biofrontera AG Stock

Equities

B8FK

DE000A4BGGM7

Pharmaceuticals

Valuation: Biofrontera AG

Chart: Biofrontera AG

Latest news: Biofrontera AG

Press Releases: Biofrontera AG

News in other languages: Biofrontera AG

Quotes and Performance

Course Extremes

Managers and Directors: Biofrontera AG

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BIOFRONTERA AG	0.00%	-1.82%	+8.69%	-91.97%	19.06M
ELI LILLY AND COMPANY	-1.85%	-8.14%	+22.25%	+170.70%	908B
JOHNSON & JOHNSON	-1.39%	-2.45%	+34.57%	+13.19%	488B
ABBVIE INC.	-0.66%	+0.46%	+29.61%	+39.75%	404B
ROCHE HOLDING AG	+0.95%	+1.79%	+22.08%	+1.08%	331B
ASTRAZENECA PLC	+0.61%	-2.75%	+27.99%	+20.69%	280B
NOVARTIS AG	+0.89%	+3.08%	+19.16%	+25.52%	256B
MERCK & CO., INC.	-1.35%	-3.57%	-0.47%	-8.32%	250B
NOVO NORDISK A/S	+2.34%	-1.32%	-59.43%	-30.54%	212B
AMGEN INC.	-1.52%	-1.28%	+22.25%	+19.14%	183B
Average	+0.48%	-1.89%	+12.67%	+15.93%	331.3B
Weighted average by Cap.	+0.37%	-3.09%	+18.25%	+55.90%

	2023	2024
Net sales	32.25M 37.61M 30.16M 28.17M 52.45M 3.38B 56.81M 354M 137M 1.6B 141M 138M 5.82B	21.67M 25.27M 20.26M 18.92M 35.23M 2.27B 38.17M 238M 91.72M 1.07B 94.83M 92.81M 3.91B
Net income	-369K -430K -345K -322K -600K -38.65M -650K -4.05M -1.56M -18.26M -1.62M -1.58M -66.6M	-4.35M -5.07M -4.07M -3.8M -7.07M -456M -7.66M -47.73M -18.42M -215M -19.04M -18.63M -785M
Net Debt	-1.93M -2.26M -1.81M -1.69M -3.15M -203M -3.41M -21.22M -8.19M -95.73M -8.46M -8.28M -349M	-2.36M -2.75M -2.21M -2.06M -3.84M -247M -4.16M -25.88M -9.99M -117M -10.33M -10.11M -426M